Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10


  Free Subscription

Articles published in J Virol

Retrieve available abstracts of 227 articles:
HTML format

Single Articles

    August 2020
  1. CROFT S, Wong YC, Smith SA, Flesch IEA, et al
    Surprisingly Effective Priming of CD8(+) T cells by Heat-Inactivated Vaccinia Virus Virions.
    J Virol. 2020 Aug 5. pii: JVI.01486-20. doi: 10.1128/JVI.01486.
    PubMed     Abstract available

    July 2020
  2. MONTICELLI SR, Bryk P, Ward BM
    The Molluscum Contagiosum Gene MC021L Partially Compensates for the Loss of Its Vaccinia Virus Homolog F13L.
    J Virol. 2020 Jul 29. pii: JVI.01496-20. doi: 10.1128/JVI.01496.
    PubMed     Abstract available

  3. SENKEVICH TG, Zhivkoplias EK, Weisberg AS, Moss B, et al
    Inactivation of genes by frameshift mutations provides rapid adaptation of an attenuated vaccinia virus.
    J Virol. 2020 Jul 15. pii: JVI.01053-20. doi: 10.1128/JVI.01053.
    PubMed     Abstract available

  4. AHLEN G, Frelin L, Nekoyan N, Weber F, et al
    The SARS-CoV-2 N protein is a good component in a vaccine.
    J Virol. 2020 Jul 13. pii: JVI.01279-20. doi: 10.1128/JVI.01279.
    PubMed     Abstract available

    June 2020
  5. MOORE JP, Klasse PJ
    SARS-CoV-2 vaccines: 'Warp Speed' needs mind melds not warped minds.
    J Virol. 2020 Jun 26. pii: JVI.01083-20. doi: 10.1128/JVI.01083.
    PubMed     Abstract available

  6. POWELL RL, Weiss S, Fox A, Liu X, et al
    An HIV vaccine targeting the V2 region of Envelope induces a highly durable polyfunctional Fc-mediated antibody response in rhesus macaques.
    J Virol. 2020 Jun 17. pii: JVI.01175-20. doi: 10.1128/JVI.01175.
    PubMed     Abstract available

  7. LI A, Xue M, Attia Z, Yu J, et al
    Vesicular stomatitis virus and DNA vaccines expressing Zika virus nonstructural protein 1 (NS1) induce substantial but not sterilizing protection against Zika virus infection.
    J Virol. 2020 Jun 17. pii: JVI.00048-20. doi: 10.1128/JVI.00048.
    PubMed     Abstract available

  8. DUTTA NK, Mazumdar K, Gordy JT
    The Nucleocapsid Protein of SARS-CoV-2: a Target for Vaccine Development.
    J Virol. 2020;94.

  9. YANG D, Sun C, Gao R, Wang H, et al
    A temperature-dependent translation defect caused by IRES mutation attenuates foot-and-mouth disease virus: Implications for rational vaccine design.
    J Virol. 2020 Jun 3. pii: JVI.00990-20. doi: 10.1128/JVI.00990.
    PubMed     Abstract available

    May 2020
  10. SCHNEIDER M, Muller M, Yigitliler A, Xi J, et al
    An Orf Virus-based therapeutic vaccine for the treatment of papillomavirus-induced tumors.
    J Virol. 2020 May 13. pii: JVI.00398-20. doi: 10.1128/JVI.00398.
    PubMed     Abstract available

    April 2020
  11. EBERHARDT CS, Wieland A, Nasti TH, Grifoni A, et al
    Persistence of varicella zoster virus specific plasma cells in adult human bone marrow following childhood vaccination.
    J Virol. 2020 Apr 22. pii: JVI.02127-19. doi: 10.1128/JVI.02127.
    PubMed     Abstract available

  12. YANG J, Ma C, Zhao Y, Fan A, et al
    Hepatitis B virus core particles containing a conserved region of the G protein combined with interleukin-35 protected mice against respiratory syncytial virus infection without vaccine-enhanced immunopathology.
    J Virol. 2020 Apr 22. pii: JVI.00007-20. doi: 10.1128/JVI.00007.
    PubMed     Abstract available

  13. RAMSEY NLM, Visciano M, Hunte R, Loh LN, et al
    A single-cycle glycoprotein D deletion viral vaccine candidate, DeltagD-2, elicits polyfunctional antibodies that protect against ocular herpes simplex virus.
    J Virol. 2020 Apr 15. pii: JVI.00335-20. doi: 10.1128/JVI.00335.
    PubMed     Abstract available

  14. CHUANG GY, Lai YT, Boyington JC, Cheng C, et al
    Development of a 3Mut-Apex-Stabilized Envelope Trimer that Expands HIV-1 Neutralization Breadth When Used To Boost Fusion Peptide-Directed Vaccine-Elicited Responses.
    J Virol. 2020 Apr 15. pii: JVI.00074-20. doi: 10.1128/JVI.00074.
    PubMed     Abstract available

  15. SHIBUYA M, Aoshi T, Kuroda E, Yoshioka Y, et al
    Murine cross-reactive non-neutralizing polyclonal IgG1 antibodies induced by influenza vaccine inhibit the cross-protective effect of IgG2 against heterologous virus in mice.
    J Virol. 2020 Apr 8. pii: JVI.00323-20. doi: 10.1128/JVI.00323.
    PubMed     Abstract available

    March 2020
  16. PATEL CD, Taylor SA, Mehrbach J, Awasthi S, et al
    Trivalent glycoprotein subunit vaccine prevents neonatal herpes simplex virus mortality and morbidity.
    J Virol. 2020 Mar 18. pii: JVI.02163-19. doi: 10.1128/JVI.02163.
    PubMed     Abstract available

  17. COTTER CA, Moss B
    Mutations Near the N-Terminus of the Vaccinia Virus G9 Protein Overcome Restrictions on Cell Entry and Syncytium Formation Imposed by the A56/K2 Fusion Regulatory Complex.
    J Virol. 2020 Mar 4. pii: JVI.00077-20. doi: 10.1128/JVI.00077.
    PubMed     Abstract available

  18. HONG GC, Tsai CH, Chang W
    Experimental evolution to isolate vaccinia virus adaptive G9 mutants that overcome membrane fusion inhibition by vaccinia A56/K2 protein complex.
    J Virol. 2020 Mar 4. pii: JVI.00093-20. doi: 10.1128/JVI.00093.
    PubMed     Abstract available

  19. GRIFONI A, Voic H, Dhanda SK, Kidd CK, et al
    T cell responses induced by attenuated flavivirus vaccination are specific and show limited cross-reactivity with other flavivirus species.
    J Virol. 2020 Mar 4. pii: JVI.00089-20. doi: 10.1128/JVI.00089.
    PubMed     Abstract available

    February 2020
  20. SINGH K, Marasini B, Chen X, Ding L, et al
    A bivalent, spherical virus-like particle vaccine enhances breadth of immune responses against pathogenic Ebola viruses in rhesus macaques.
    J Virol. 2020 Feb 19. pii: JVI.01884-19. doi: 10.1128/JVI.01884.
    PubMed     Abstract available

  21. NELSON CS, Jenks JA, Pardi N, Goodwin M, et al
    HCMV glycoprotein B nucleoside-modified mRNA vaccine elicits antibody responses with greater durability and breadth than MF59-adjuvanted gB protein immunization.
    J Virol. 2020 Feb 12. pii: JVI.00186-20. doi: 10.1128/JVI.00186.
    PubMed     Abstract available

    January 2020
  22. MANNING JT, Yun NE, Seregin AV, Koma T, et al
    The glycoprotein of the live-attenuated Junin virus vaccine strain induces ER stress and forms aggregates prior to degradation in the lysosome.
    J Virol. 2020 Jan 29. pii: JVI.01693-19. doi: 10.1128/JVI.01693.
    PubMed     Abstract available

  23. BORCA MV, Ramirez-Medina E, Silva E, Vuono E, et al
    Development of a highly effective African swine fever virus vaccine by deletion of the I177L gene results in sterile immunity against the current epidemic Eurasia strain.
    J Virol. 2020 Jan 22. pii: JVI.02017-19. doi: 10.1128/JVI.02017.
    PubMed     Abstract available

  24. FUERY A, Pursell T, Tan J, Peng R, et al
    Lethal Hemorrhagic Disease and Clinical Illness Associated with Elephant Endotheliotropic Herpesvirus 1 Are Caused by Primary Infection: Implications for the Detection of Diagnostic Proteins.
    J Virol. 2020;94.
    PubMed     Abstract available

  25. MONTICELLI SR, Earley AK, Stone R, Norbury CC, et al
    Vaccinia Virus Glycoproteins A33, A34, and B5 Form a Complex for Efficient Endoplasmic Reticulum to trans-Golgi Network Transport.
    J Virol. 2020 Jan 15. pii: JVI.02155-19. doi: 10.1128/JVI.02155.
    PubMed     Abstract available

  26. WANG S, Voronin Y, Zhao P, Ishihara M, et al
    Glycan profiles of gp120 protein vaccines from four major HIV-1 subtypes produced from different host cell lines under non-GMP or GMP conditions.
    J Virol. 2020 Jan 15. pii: JVI.01968-19. doi: 10.1128/JVI.01968.
    PubMed     Abstract available

  27. MA S, Zhang B, Shi J, Yin X, et al
    Amino Acid Mutations A286V and T437M in the Nucleoprotein Attenuate H7N9 Viruses in Mice.
    J Virol. 2020;94.
    PubMed     Abstract available

  28. XUE Q, Xu H, Liu H, Pan J, et al
    Epitope Containing Short Peptides Capture Distinct IgG Serodynamics that Enable DIVA for Live-attenuated Vaccines.
    J Virol. 2020 Jan 2. pii: JVI.01573-19. doi: 10.1128/JVI.01573.
    PubMed     Abstract available

  29. IMURA A, Sudaka Y, Takashino A, Tamura K, et al
    Development of an enterovirus 71 vaccine efficacy test using human scavenger receptor B2 transgenic mice.
    J Virol. 2020 Jan 2. pii: JVI.01921-19. doi: 10.1128/JVI.01921.
    PubMed     Abstract available

    December 2019
  30. VERMA A, Schmidt BA, Elizaldi SR, Nguyen NK, et al
    Impact of Th1 CD4 TFH skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques.
    J Virol. 2019 Dec 11. pii: JVI.01737-19. doi: 10.1128/JVI.01737.
    PubMed     Abstract available

  31. CHIUPPESI F, Nguyen J, Park S, Contreras H, et al
    Correction for Chiuppesi et al., "Multiantigenic Modified Vaccinia Virus Ankara Vaccine Vectors To Elicit Potent Humoral and Cellular Immune Responses against Human Cytomegalovirus in Mice".
    J Virol. 2019;93.

    November 2019
  32. SMITH A, Rodriguez L, Ghouayel ME, Nogales A, et al
    A live-attenuated influenza vaccine (LAIV) elicits enhanced heterologous protection when the internal genes of the vaccine are matched to the challenge virus.
    J Virol. 2019 Nov 20. pii: JVI.01065-19. doi: 10.1128/JVI.01065.
    PubMed     Abstract available

  33. RIJAL P, Wang BB, Tan TK, Schimanski L, et al
    Broadly inhibiting anti-neuraminidase monoclonal antibodies induced by trivalent influenza vaccine and H7N9 infection in humans.
    J Virol. 2019 Nov 20. pii: JVI.01182-19. doi: 10.1128/JVI.01182.
    PubMed     Abstract available

  34. RUSSIER M, Yang G, Briard B, Meliopoulos V, et al
    HA stability regulates H1N1 influenza virus replication and pathogenicity in mice by modulating type I interferon responses in dendritic cells.
    J Virol. 2019 Nov 6. pii: JVI.01423-19. doi: 10.1128/JVI.01423.
    PubMed     Abstract available

    October 2019
  35. BOPPANA S, Fiore-Gartland A, Bansal A, Goepfert P, et al
    Cross-reactive CD8 T-cell responses elicited by Ad5-based HIV-1 vaccines contributed to early viral evolution in vaccine recipients who became infected.
    J Virol. 2019 Oct 23. pii: JVI.01632-19. doi: 10.1128/JVI.01632.
    PubMed     Abstract available

  36. HAHN AS, Bischof GF, Grosskopf AK, Shin YC, et al
    A Recombinant Rhesus Monkey Rhadinovirus Deleted of Glycoprotein L Establishes Persistent Infection of Rhesus Macaques and Elicits Conventional T Cell Responses.
    J Virol. 2019 Oct 23. pii: JVI.01093-19. doi: 10.1128/JVI.01093.
    PubMed     Abstract available

  37. RINGE RP, Colin P, Torres JL, Yasmeen A, et al
    SOS and IP modifications predominantly affect the yield but not other properties of SOSIP.664 HIV-1 Env glycoprotein trimers.
    J Virol. 2019 Oct 16. pii: JVI.01521-19. doi: 10.1128/JVI.01521.
    PubMed     Abstract available

  38. BOUKHVALOVA MS, Mortensen E, Mbaye A, Lopez D, et al
    Herpes Simplex Virus 1 induces brain inflammation and multifocal demyelination in cotton rats Sigmodon hispidus.
    J Virol. 2019 Oct 9. pii: JVI.01161-19. doi: 10.1128/JVI.01161.
    PubMed     Abstract available

    September 2019
  39. YE L, Ohnemus A, Ong LC, Gad HH, et al
    Type I and type III interferons differ in their adjuvant activities for influenza vaccines.
    J Virol. 2019 Sep 11. pii: JVI.01262-19. doi: 10.1128/JVI.01262.
    PubMed     Abstract available

  40. LIU Y, Freed DC, Li L, Tang A, et al
    A Replication Defective Human Cytomegalovirus Vaccine Elicits Humoral Immune Responses Analogous to Those with Natural Infection.
    J Virol. 2019 Sep 11. pii: JVI.00747-19. doi: 10.1128/JVI.00747.
    PubMed     Abstract available

  41. BLANCO JCG, Fernando LR, Zhang W, Kamali A, et al
    Alternative Virus-Like Particle-Associated Pre-Fusion F Proteins as Maternal Vaccines for Respiratory Syncytial Virus.
    J Virol. 2019 Sep 11. pii: JVI.00914-19. doi: 10.1128/JVI.00914.
    PubMed     Abstract available

  42. CHOI KY, El-Hamdi NS, McGregor A
    Inclusion of the viral pentamer complex in a vaccine design greatly improves protection against congenital cytomegalovirus in the guinea pig model.
    J Virol. 2019 Sep 4. pii: JVI.01442-19. doi: 10.1128/JVI.01442.
    PubMed     Abstract available

  43. BYRD-LEOTIS L, Gao C, Jia N, Mehta A, et al
    Antigenic pressure on H3N2 influenza drift strains imposes constraints on binding to sialylated receptors, but not phosphorylated glycans.
    J Virol. 2019 Sep 4. pii: JVI.01178-19. doi: 10.1128/JVI.01178.
    PubMed     Abstract available

    August 2019
  44. JOHNSON J, Freedman H, Logan M, Wong JAJ, et al
    A recombinant HCV genotype 1a E1/E2 envelope glycoprotein vaccine elicits antibodies that differentially neutralize closely related 2a strains through interactions of the N-terminal hypervariable region 1 of E2 with scavenger receptor B1.
    J Virol. 2019 Aug 28. pii: JVI.00810-19. doi: 10.1128/JVI.00810.
    PubMed     Abstract available

  45. SLIVA K, Martin J, von Rhein C, Herrmann T, et al
    Interference with SAMHD1 restores late gene expression of modified vaccinia virus Ankara (MVA) in human dendritic cells and abrogates type I interferon expression.
    J Virol. 2019 Aug 28. pii: JVI.01097-19. doi: 10.1128/JVI.01097.
    PubMed     Abstract available

  46. LI SS, Gilbert PB, Carpp LN, Pyo CW, et al
    Fc gamma receptor polymorphisms modulated the vaccine effect on HIV-1 risk in the HVTN 505 HIV vaccine trial.
    J Virol. 2019 Aug 21. pii: JVI.02041-18. doi: 10.1128/JVI.02041.
    PubMed     Abstract available

  47. HENRY C, Palm AE, Utset HA, Huang M, et al
    Monoclonal antibody responses after recombinant HA vaccine versus subunit inactivated influenza virus vaccine: a comparative study.
    J Virol. 2019 Aug 21. pii: JVI.01150-19. doi: 10.1128/JVI.01150.
    PubMed     Abstract available

  48. ALMOND N, Berry N, Stebbings R, Preston M, et al
    Vaccination of macaques with DNA followed by adenoviral vectors encoding SIV gag alone delays infection by repeated mucosal challenge with SIV.
    J Virol. 2019 Aug 14. pii: JVI.00606-19. doi: 10.1128/JVI.00606.
    PubMed     Abstract available

  49. DHAKAL S, Klein SL
    Host factors impact vaccine efficacy: implications for seasonal and universal influenza vaccine programs.
    J Virol. 2019 Aug 7. pii: JVI.00797-19. doi: 10.1128/JVI.00797.
    PubMed     Abstract available

  50. DU C, Duan Y, Wang X, Lin Y, et al
    Attenuation of equine lentivirus alters mitochondrial protein expression profile from inflammation to apoptosis.
    J Virol. 2019 Aug 7. pii: JVI.00653-19. doi: 10.1128/JVI.00653.
    PubMed     Abstract available

  51. WONG YC, Croft S, Smith SA, Lin LCW, et al
    Vaccinia Virus Strain MVA can Induce Optimal CD8(+) T cell responses to Directly Primed Antigens Depending on Vaccine Design.
    J Virol. 2019 Aug 2. pii: JVI.01154-19. doi: 10.1128/JVI.01154.
    PubMed     Abstract available

  52. HRYCAK CP, Windmann S, Bayer W
    Comparative evaluation of the vaccine efficacy of three adenovirus-based vector types in the Friend retrovirus infection model.
    J Virol. 2019 Aug 2. pii: JVI.01155-19. doi: 10.1128/JVI.01155.
    PubMed     Abstract available

  53. GACH JS, Mara KJV, LaBranche CC, van Gils MJ, et al
    Antibody responses elicited by immunization with BG505 trimer-immune complexes.
    J Virol. 2019 Aug 2. pii: JVI.01188-19. doi: 10.1128/JVI.01188.
    PubMed     Abstract available

  54. BROECKER F, Zheng A, Suntrongwong N, Sun W, et al
    Extending the stalk enhances immunogenicity of the influenza virus neuraminidase.
    J Virol. 2019 Aug 2. pii: JVI.00840-19. doi: 10.1128/JVI.00840.
    PubMed     Abstract available

    July 2019
  55. RICO AB, Wang Z, Olson AT, Linville AC, et al
    The Vaccinia B1 and Cellular VRK2 Kinases Promote Vaccinia Replication Factory Formation through Phosphorylation Dependent Inhibition of Vaccinia B12.
    J Virol. 2019 Jul 24. pii: JVI.00855-19. doi: 10.1128/JVI.00855.
    PubMed     Abstract available

  56. STYLES TM, Gangadhara S, Reddy PBJ, Hicks S, et al
    HIV C.1086 Envelope Gp140 Protein Boosts Following DNA/MVA Vaccination Fail to Enhance Heterologous Anti-V1V2 Antibody Response and Protection Against Clade C SHIV Challenge.
    J Virol. 2019 Jul 24. pii: JVI.00934-19. doi: 10.1128/JVI.00934.
    PubMed     Abstract available

  57. RATTAN A, Richards KA, Knowlden ZAG, Sant AJ, et al
    Protein vaccination directs the CD4+ T cell response towards shared protective epitopes that can be recalled after influenza infection.
    J Virol. 2019 Jul 24. pii: JVI.00947-19. doi: 10.1128/JVI.00947.
    PubMed     Abstract available

  58. NOTARIO L, Redondo-Anton J, Alari-Pahissa E, Albentosa A, et al
    CD69 targeting enhances anti-Vaccinia virus immunity.
    J Virol. 2019 Jul 17. pii: JVI.00553-19. doi: 10.1128/JVI.00553.
    PubMed     Abstract available

  59. ABDULHAQQ SA, Wu H, Schell JB, Hammond KB, et al
    Vaccine-mediated Inhibition of the Transporter Associated with Antigen Processing is Insufficient to Induce MHC-E Restricted CD8+ T cells in Nonhuman Primates.
    J Virol. 2019 Jul 17. pii: JVI.00592-19. doi: 10.1128/JVI.00592.
    PubMed     Abstract available

  60. REY LM, Gil JA, Mateus J, Rodriguez LS, et al
    LAP(+) cells modulate protection induced by oral vaccination with Rhesus Rotavirus in a neonatal mouse model.
    J Virol. 2019 Jul 10. pii: JVI.00882-19. doi: 10.1128/JVI.00882.
    PubMed     Abstract available

  61. MEKONNEN ZA, Grubor-Bauk B, English K, Leung P, et al
    Single dose vaccination with a hepatotropic Adeno-associated virus (AAV) efficiently localises T cell immunity in the liver with the potential to confer rapid protection against hepatitis C virus (HCV).
    J Virol. 2019 Jul 10. pii: JVI.00202-19. doi: 10.1128/JVI.00202.
    PubMed     Abstract available

  62. SHEPHERD N, Lan J, Li W, Rane S, et al
    Primary human B cells at different differentiation and maturation stages exhibit distinct susceptibilities to vaccinia virus binding and infection.
    J Virol. 2019 Jul 10. pii: JVI.00973-19. doi: 10.1128/JVI.00973.
    PubMed     Abstract available

  63. LI X, Gao Y, Ye Z
    A Single Amino Acid Substitution at Residue 218 of Hemagglutinin Improves the Growth of Influenza A(H7N9) Candidate Vaccine Viruses.
    J Virol. 2019 Jul 3. pii: JVI.00570-19. doi: 10.1128/JVI.00570.
    PubMed     Abstract available

  64. CARRAU L, Rezelj VV, Noval MG, Levi LI, et al
    Chikungunya virus vaccine candidates with decreased mutational robustness are attenuated in vivo and have compromised transmissibility.
    J Virol. 2019 Jul 3. pii: JVI.00775-19. doi: 10.1128/JVI.00775.
    PubMed     Abstract available

    June 2019
  65. ALFAJARO MM, Kim JY, Barbe L, Cho EH, et al
    Dual Recognition of Sialic Acid and alphaGal Epitopes by the VP8* Domains of the Bovine Rotavirus G6P[5] WC3 and of Its Mono-reassortant G4P[5] RotaTeq Vaccine Strains.
    J Virol. 2019 Jun 26. pii: JVI.00941-19. doi: 10.1128/JVI.00941.
    PubMed     Abstract available

  66. PASIN C, Balelli I, Van Effelterre T, Bockstal V, et al
    Dynamics of the humoral immune response to a prime-boost Ebola vaccine: quantification and sources of variation.
    J Virol. 2019 Jun 26. pii: JVI.00579-19. doi: 10.1128/JVI.00579.
    PubMed     Abstract available

  67. ROY S, Coulon PG, Prakash S, Srivastava R, et al
    Blockade of PD-1 and LAG-3 Immune Checkpoints Combined with Vaccination Restore the Function of Anti-Viral Tissue-Resident CD8(+) TRM Cells and Reduce Ocular Herpes Simplex Infection and Disease in HLA Transgenic Rabbits.
    J Virol. 2019 Jun 19. pii: JVI.00827-19. doi: 10.1128/JVI.00827.
    PubMed     Abstract available

  68. TAI W, Chen J, Zhao G, Geng Q, et al
    Rational design of Zika virus subunit vaccine with enhanced efficacy.
    J Virol. 2019 Jun 12. pii: JVI.02187-18. doi: 10.1128/JVI.02187.
    PubMed     Abstract available

  69. LI N, Zhang YN, Deng CL, Shi PY, et al
    Replication-defective West Nile virus with NS1 deletion as a new vaccine platform for flavivirus.
    J Virol. 2019 Jun 12. pii: JVI.00720-19. doi: 10.1128/JVI.00720.
    PubMed     Abstract available

  70. ZOLLA-PAZNER S, Gilbert PB
    J Virol. 2019 Jun 12. pii: JVI.00629-19. doi: 10.1128/JVI.00629.
    PubMed     Abstract available

  71. LEHMANN C, Falk JJ, Buscher N, Penner I, et al
    Dense bodies of a gH/gL/UL128-131 pentamer repaired Towne strain of human cytomegalovirus induce an enhanced neutralizing antibody response.
    J Virol. 2019 Jun 12. pii: JVI.00931-19. doi: 10.1128/JVI.00931.
    PubMed     Abstract available

  72. KIM JI, Lee S, Lee GY, Park S, et al
    Novel small molecule targeting the hemagglutinin stalk of influenza viruses.
    J Virol. 2019 Jun 5. pii: JVI.00878-19. doi: 10.1128/JVI.00878.
    PubMed     Abstract available

    May 2019
  73. HOU Y, Ke H, Kim J, Yoo D, et al
    Engineering a live attenuated PEDV vaccine candidate via inactivation of the viral 2'-O methyltransferase and the endocytosis signal of the spike protein.
    J Virol. 2019 May 22. pii: JVI.00406-19. doi: 10.1128/JVI.00406.
    PubMed     Abstract available

  74. MEADE N, King M, Munger J, Walsh D, et al
    mTOR dysregulation by vaccinia virus F17 controls multiple processes with varying roles in infection.
    J Virol. 2019 May 22. pii: JVI.00784-19. doi: 10.1128/JVI.00784.
    PubMed     Abstract available

  75. WEINBERG A, Pang L, Johnson MJ, Caldas Y, et al
    The Effect of Age on the Immunogenicity of the Live Attenuated Zoster Vaccine Is Predicted by Baseline Regulatory T Cells and VZV-Specific T Cell Immunity.
    J Virol. 2019 May 15. pii: JVI.00305-19. doi: 10.1128/JVI.00305.
    PubMed     Abstract available

  76. ZHANG YN, Deng CL, Li JQ, Li N, et al
    Infectious Chikungunya Virus with a Complete Capsid Deletion: a New Approach for CHIKV Vaccine.
    J Virol. 2019 May 15. pii: JVI.00504-19. doi: 10.1128/JVI.00504.
    PubMed     Abstract available

  77. JONES DI, Pollara JJ, Johnson-Weaver BT, LaBranche CC, et al
    Optimized Mucosal MVA Prime/Soluble gp120 Boost Vaccination Regimen Induces Similar Antibody Responses as an Intramuscular Regimen.
    J Virol. 2019 May 8. pii: JVI.00475-19. doi: 10.1128/JVI.00475.
    PubMed     Abstract available

  78. MCGINNES CULLEN L, Schmidt MR, Morrison TG
    Effect of Previous Respiratory Syncytial Virus Infection on Murine Immune Responses to F and G Protein-Containing Virus-Like Particles.
    J Virol. 2019;93.
    PubMed     Abstract available

    April 2019
  79. GOFFIN E, Javaux J, Destexhe E, Pretto CD, et al
    Oral vaccination with replication-competent adenovirus in mice reveals the dissemination of the viral vaccine beyond the gastrointestinal tract.
    J Virol. 2019 Apr 17. pii: JVI.00237-19. doi: 10.1128/JVI.00237.
    PubMed     Abstract available

  80. PANT A, Cao S, Yang Z
    Asparagine is a critical limiting metabolite for vaccinia virus protein synthesis during glutamine deprivation.
    J Virol. 2019 Apr 17. pii: JVI.01834-18. doi: 10.1128/JVI.01834.
    PubMed     Abstract available

  81. CALATAYUD O, Esperon F, Cleaveland S, Biek R, et al
    Carnivore parvovirus ecology in the Serengeti ecosystem: vaccine strains circulating and new host species identified.
    J Virol. 2019 Apr 17. pii: JVI.02220-18. doi: 10.1128/JVI.02220.
    PubMed     Abstract available

  82. LUTEIJN RD, van Diemen F, Blomen VA, Boer IGJ, et al
    A genome-wide haploid genetic screen identifies heparan sulfate-associated genes and the macropinocytosis modulator TMED10 as factors supporting vaccinia virus infection.
    J Virol. 2019 Apr 17. pii: JVI.02160-18. doi: 10.1128/JVI.02160.
    PubMed     Abstract available

  83. TSAI YH, Huang SW, Hsieh WS, Cheng CK, et al
    Enterovirus A71 Containing Codon-Deoptimized VP1 and High-Fidelity Polymerase as Next Generation Vaccine Candidate.
    J Virol. 2019 Apr 17. pii: JVI.02308-18. doi: 10.1128/JVI.02308.
    PubMed     Abstract available

  84. BORENSTEIN-KATZ A, Shulman A, Hamawi H, Leitner O, et al
    Differential Antibody-Based Immune Response against Isolated GP1 Receptor-Binding Domains from Lassa and Junin Viruses.
    J Virol. 2019;93.
    PubMed     Abstract available

  85. SUN W, Kirkpatrick E, Ermler M, Nachbagauer R, et al
    Development of Influenza B Universal Vaccine Candidates using the "Mosaic" Hemagglutinin Approach.
    J Virol. 2019 Apr 3. pii: JVI.00333-19. doi: 10.1128/JVI.00333.
    PubMed     Abstract available

    March 2019
  86. KLEINPETER P, Remy-Ziller C, Winter E, Gantzer M, et al
    By binding CD80 and CD86, the vaccinia virus' M2 protein blocks their interactions with both CD28 and CTLA4 and potentiates CD80's binding to PD-L1.
    J Virol. 2019 Mar 27. pii: JVI.00207-19. doi: 10.1128/JVI.00207.
    PubMed     Abstract available

  87. POLLARA J, Jones DI, Huffman T, Edwards RW, et al
    Bridging vaccine-induced HIV-1 neutralizing and effector antibody responses in rabbit and rhesus macaque animal models.
    J Virol. 2019 Mar 6. pii: JVI.02119-18. doi: 10.1128/JVI.02119.
    PubMed     Abstract available

  88. MATCHETT WE, Anguiano-Zarate SS, Nehete PN, Shelton K, et al
    Divergent HIV-1 Directed Immune Responses Generated by Systemic and Mucosal Immunization with Replicating Single-Cycle Adenoviruses in Rhesus Macaques.
    J Virol. 2019 Mar 6. pii: JVI.02016-18. doi: 10.1128/JVI.02016.
    PubMed     Abstract available

  89. WANG H, Wong G, Zhu W, He S, et al
    Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease.
    J Virol. 2019;93.
    PubMed     Abstract available

  90. GROSS DA, Ghenassia A, Bartolo L, Urbain D, et al
    Cross-Presentation of Skin-Targeted Recombinant Adeno-associated Virus 2/1 Transgene Induces Potent Resident Memory CD8(+) T Cell Responses.
    J Virol. 2019;93.
    PubMed     Abstract available

    February 2019
  91. PALLETT MA, Ren H, Zhang RY, Scutts SR, et al
    Vaccinia virus BBK E3 ligase adaptor A55 targets importin-dependent NF-kappaB activation and inhibits CD8(+) T-cell memory.
    J Virol. 2019 Feb 27. pii: JVI.00051-19. doi: 10.1128/JVI.00051.
    PubMed     Abstract available

  92. SRIVASTAVA R, Roy S, Coulon PA, Vahed H, et al
    Therapeutic Mucosal Vaccination of HSV-2 Infected Guinea Pigs with the Ribonucleotide Reductase 2 (RR2) Protein Boosts Antiviral Neutralizing Antibodies and Tissue-Resident CD4(+) and CD8(+) TRM Cells Associated with Protection Against Recurrent Genit
    J Virol. 2019 Feb 20. pii: JVI.02309-18. doi: 10.1128/JVI.02309.
    PubMed     Abstract available

  93. VAN DIEPEN MT, Chapman R, Douglass N, Galant S, et al
    Prime boost immunisations with DNA, MVA and protein-based vaccines elicit robust HIV-1, Tier 2 neutralizing antibodies against the CAP256 superinfecting virus.
    J Virol. 2019 Feb 13. pii: JVI.02155-18. doi: 10.1128/JVI.02155.
    PubMed     Abstract available

  94. WU Q, Rivailler P, Xu S, Xu W, et al
    Comparison of the whole genome sequence of an Oka varicella vaccine from China with other Oka vaccine strains reveals sites putatively critical for vaccine efficacy.
    J Virol. 2019 Feb 6. pii: JVI.02281-18. doi: 10.1128/JVI.02281.
    PubMed     Abstract available

    January 2019
  95. TAY MZ, Kunz EL, Deal A, Zhang L, et al
    Rare Detection of Antiviral Functions of Polyclonal IgA Isolated from Plasma and Breast Milk Compartments in HIV-1 Chronically Infected Women.
    J Virol. 2019 Jan 30. pii: JVI.02084-18. doi: 10.1128/JVI.02084.
    PubMed     Abstract available

  96. ZOU C, Murakoshi H, Kuse N, Akahoshi T, et al
    Effective Suppression of HIV-1 Replication by Cytotoxic T Lymphocytes Specific for Pol Epitopes in Conserved Mosaic Vaccine Immunogens.
    J Virol. 2019 Jan 23. pii: JVI.02142-18. doi: 10.1128/JVI.02142.
    PubMed     Abstract available

  97. MARIN MQ, Perez P, Ljungberg K, Sorzano COS, et al
    Potent Anti-Hepatitis C (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-launched RNA Replicons and MVA-HCV.
    J Virol. 2019 Jan 23. pii: JVI.00055-19. doi: 10.1128/JVI.00055.
    PubMed     Abstract available

  98. BURTON S, Spicer LM, Charles TP, Gangadhara S, et al
    Clade C HIV-1 envelope vaccination regimens differ in their ability to elicit antibodies with moderate neutralization breadth against genetically diverse tier 2 HIV-1 envelope variants.
    J Virol. 2019 Jan 16. pii: JVI.01846-18. doi: 10.1128/JVI.01846.
    PubMed     Abstract available

  99. LI ZT, Zarnitsyna VI, Lowen AC, Weissman D, et al
    Why Are CD8 T Cell Epitopes of Human Influenza A Virus Conserved?
    J Virol. 2019 Jan 9. pii: JVI.01534-18. doi: 10.1128/JVI.01534.
    PubMed     Abstract available

  100. ARUNKUMAR GA, Ioannou A, Wohlbold TJ, Meade P, et al
    Broadly cross-reactive, non-neutralizing antibodies against the influenza B virus hemagglutinin demonstrate effector function dependent protection against lethal viral challenge in mice.
    J Virol. 2019 Jan 9. pii: JVI.01696-18. doi: 10.1128/JVI.01696.
    PubMed     Abstract available

    December 2018
  101. DE FREITAS LFD, Oliveira RP, Miranda MCG, Rocha RP, et al
    The virulence of different Vaccinia virus strains is directly proportional to their ability in down modulating specific cell-mediated immune compartments in vivo.
    J Virol. 2018 Dec 19. pii: JVI.02191-18. doi: 10.1128/JVI.02191.
    PubMed     Abstract available

  102. OBADAN AO, Santos J, Ferreri L, Thompson AJ, et al
    Flexibility in vitro of amino acid 226 in the receptor-binding site of an H9 subtype influenza A virus and its effect in vivo on virus replication, tropism, and transmission.
    J Virol. 2018 Dec 19. pii: JVI.02011-18. doi: 10.1128/JVI.02011.
    PubMed     Abstract available

  103. KESHWARA R, Hagen KR, Abreu-Mota T, Papaneri AB, et al
    A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein is Dependent Upon ADCC for Protection Against Marburg Virus Disease in a Murine Model.
    J Virol. 2018 Dec 19. pii: JVI.01865-18. doi: 10.1128/JVI.01865.
    PubMed     Abstract available

  104. MOSHKANI S, Chiale C, Lang SM, Rose JK, et al
    A highly attenuated vesicular stomatitis virus-based vaccine platform controls HBV replication in mouse models of hepatitis B.
    J Virol. 2018 Dec 12. pii: JVI.01586-18. doi: 10.1128/JVI.01586.
    PubMed     Abstract available

  105. MARTINS MA, Gonzalez-Nieto L, Shin YC, Domingues A, et al
    Vaccine-induced T-cell responses do not predict the rate of acquisition after repeated intrarectal SIVmac239 challenges in Mamu-B*08+ rhesus macaques.
    J Virol. 2018 Dec 12. pii: JVI.01626-18. doi: 10.1128/JVI.01626.
    PubMed     Abstract available

  106. DENNIS M, Eudailey J, Pollara J, McMillan AS, et al
    Co-administration of CH31 broadly neutralizing antibody does not affect development of vaccine-induced anti-HIV-1 envelope antibody responses in infant Rhesus macaques.
    J Virol. 2018 Dec 12. pii: JVI.01783-18. doi: 10.1128/JVI.01783.
    PubMed     Abstract available

  107. CHEA LS, Wyatt LS, Gangadhara S, Moss B, et al
    Novel MVA Vector Expressing Anti-apoptotic Gene B13R Delays Apoptosis and Enhances Humoral Responses.
    J Virol. 2018 Dec 12. pii: JVI.01648-18. doi: 10.1128/JVI.01648.
    PubMed     Abstract available

  108. KIMBLE JB, Malherbe DC, Meyer M, Gunn BM, et al
    J Virol. 2018 Dec 5. pii: JVI.01845-18. doi: 10.1128/JVI.01845.
    PubMed     Abstract available

  109. NELSON CS, Cruz DV, Su M, Xie G, et al
    Intrahost dynamics of human cytomegalovirus variants acquired by seronegative glycoprotein B vaccinees.
    J Virol. 2018 Dec 5. pii: JVI.01695-18. doi: 10.1128/JVI.01695.
    PubMed     Abstract available

  110. CHEN YQ, Lan LY, Huang M, Henry C, et al
    Hemagglutinin stalk-reactive antibodies interfere with influenza virus neuraminidase activity by steric hindrance.
    J Virol. 2018 Dec 5. pii: JVI.01526-18. doi: 10.1128/JVI.01526.
    PubMed     Abstract available

    November 2018
  111. RINGE RP, Pugach P, Cottrell CA, LaBranche CC, et al
    Closing and opening holes in the glycan shield of HIV-1 envelope glycoprotein SOSIP trimers can redirect the neutralizing antibody response to the newly unmasked epitopes.
    J Virol. 2018 Nov 28. pii: JVI.01656-18. doi: 10.1128/JVI.01656.
    PubMed     Abstract available

  112. MONTICELLI SR, Earley AK, Tate J, Ward BM, et al
    The Ectodomain of the Vaccinia Virus Glycoprotein A34 is Required for Cell Binding by Extracellular Virions and Contains a Large Region Capable of Interaction with the Glycoprotein B5.
    J Virol. 2018 Nov 21. pii: JVI.01343-18. doi: 10.1128/JVI.01343.
    PubMed     Abstract available

  113. HELMOLD HAIT S, Vargas-Inchaustegui DA, Musich T, Mohanram V, et al
    Early T follicular helper cell responses and germinal center reactions are associated with viremia control in immunized Rhesus macaques.
    J Virol. 2018 Nov 21. pii: JVI.01687-18. doi: 10.1128/JVI.01687.
    PubMed     Abstract available

  114. ASBACH B, Kibler KV, Kostler J, Perdiguero B, et al
    Priming with a potent HIV-1 DNA vaccine frames the quality of immune responses prior to a poxvirus and protein boost.
    J Virol. 2018 Nov 14. pii: JVI.01529-18. doi: 10.1128/JVI.01529.
    PubMed     Abstract available

  115. NURNBERGER C, Bodmer BS, Fiedler AH, Gabriel G, et al
    A measles virus-based vaccine candidate mediates protection against Zika virus in an allogenic mouse pregnancy model.
    J Virol. 2018 Nov 14. pii: JVI.01485-18. doi: 10.1128/JVI.01485.
    PubMed     Abstract available

  116. ALLEN JD, Jang H, DiNapoli J, Kleanthous H, et al
    Elicitation of protective antibodies against 20 years of future H3N2 co-ciruculating influenza virus variants in ferrets preimmune to historical H3N2 influenza viruses.
    J Virol. 2018 Nov 14. pii: JVI.00946-18. doi: 10.1128/JVI.00946.
    PubMed     Abstract available

  117. KIBLER KV, Asbach B, Perdiguero B, Garcia-Arriaza J, et al
    Replication-competent NYVAC-KC yields improved immunogenicity to HIV-1 antigens in rhesus macaques, compared to non-replicating NYVAC.
    J Virol. 2018 Nov 14. pii: JVI.01513-18. doi: 10.1128/JVI.01513.
    PubMed     Abstract available

    October 2018
  118. HUSSAIN S, Turnbull ML, Wise HM, Jagger BW, et al
    Mutation of influenza A virus PA-X decreases pathogenicity in chicken embryos and can increase the yield of reassortant candidate vaccine viruses.
    J Virol. 2018 Oct 31. pii: JVI.01551-18. doi: 10.1128/JVI.01551.
    PubMed     Abstract available

  119. SUN W, Kang DS, Zheng A, Liu STH, et al
    Antibody responses towards the major antigenic sites of influenza B virus hemagglutinin in mice, ferrets and humans.
    J Virol. 2018 Oct 31. pii: JVI.01673-18. doi: 10.1128/JVI.01673.
    PubMed     Abstract available

  120. PRACHANRONARONG KL, Canale AS, Liu P, Somasundaran M, et al
    Mutations in influenza A virus neuraminidase and hemagglutinin confer resistance against a broadly neutralizing hemagglutinin stem antibody.
    J Virol. 2018 Oct 31. pii: JVI.01639-18. doi: 10.1128/JVI.01639.
    PubMed     Abstract available

  121. AN Y, Parsons LM, Jankowska E, Melnyk D, et al
    N-Glycosylation of Seasonal Influenza Vaccine Hemagglutinins: Implication for potency testing and immune processing.
    J Virol. 2018 Oct 24. pii: JVI.01693-18. doi: 10.1128/JVI.01693.
    PubMed     Abstract available

  122. OGDEN KM, Tan Y, Akopov A, Stewart LS, et al
    Multiple introductions and antigenic mismatch with vaccines may contribute to increased predominance of G12P[8] rotaviruses in the United States.
    J Virol. 2018 Oct 17. pii: JVI.01476-18. doi: 10.1128/JVI.01476.
    PubMed     Abstract available

  123. MURAKOSHI H, Kuse N, Akahoshi T, Yu Z, et al
    Broad recognition of circulating HIV-1 by HIV-1-specific CTLs with strong ability to suppress HIV-1 replication.
    J Virol. 2018 Oct 17. pii: JVI.01480-18. doi: 10.1128/JVI.01480.
    PubMed     Abstract available

  124. KINLOCH NN, Lee GQ, Carlson JM, Jin SW, et al
    Genotypic and Mechanistic Characterization of Subtype-specific HIV Adaptation to Host Cellular Immunity.
    J Virol. 2018 Oct 10. pii: JVI.01502-18. doi: 10.1128/JVI.01502.
    PubMed     Abstract available

    September 2018
  125. HODGSON S, Moffat K, Hill H, Flannery JT, et al
    Comparison of the immunogenicity and cross-lineage efficacy of live attenuated peste des petits ruminants virus vaccines PPRV/Nigeria/75/1 and PPRV/Sungri/96.
    J Virol. 2018 Sep 26. pii: JVI.01471-18. doi: 10.1128/JVI.01471.
    PubMed     Abstract available

  126. FREI JC, Wirchnianski AS, Govero J, Vergnolle O, et al
    Engineered Dengue Virus Domain III Proteins Elicit Cross-Neutralizing Antibody Responses in Mice.
    J Virol. 2018;92.
    PubMed     Abstract available

  127. SIVAN G, Glushakow-Smith SG, Katsafanas GC, Americo JL, et al
    Human host-range restriction of the vaccinia virus C7/K1 double deletion mutant is mediated by an atypical mode of translation inhibition.
    J Virol. 2018 Sep 12. pii: JVI.01329-18. doi: 10.1128/JVI.01329.
    PubMed     Abstract available

  128. PISSANI F, Schulte B, Eller MA, Schultz BT, et al
    Modulation of Vaccine-induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans.
    J Virol. 2018 Sep 12. pii: JVI.01143-18. doi: 10.1128/JVI.01143.
    PubMed     Abstract available

  129. TSAI WY, Chen HL, Tsai JJ, Dejnirattisai W, et al
    Potent neutralizing human monoclonal antibodies preferentially target mature dengue virus particles: implication for novel strategy of dengue vaccine.
    J Virol. 2018 Sep 5. pii: JVI.00556-18. doi: 10.1128/JVI.00556.
    PubMed     Abstract available

  130. DARRICARRERE N, Pougatcheva S, Duan X, Rudicell RS, et al
    Development of a Pan-H1 Influenza Vaccine.
    J Virol. 2018 Sep 5. pii: JVI.01349-18. doi: 10.1128/JVI.01349.
    PubMed     Abstract available

  131. ABENTE EJ, Rajao DS, Santos J, Kaplan BS, et al
    Comparison of adjuvanted-whole inactivated virus and live-attenuated virus vaccines against challenge with contemporary, antigenically distinct swine H3N2 influenza A viruses.
    J Virol. 2018 Sep 5. pii: JVI.01323-18. doi: 10.1128/JVI.01323.
    PubMed     Abstract available

  132. DAVIDO DJ, Tu EM, Wang H, Korom M, et al
    Attenuated Herpes Simplex Virus 1 (HSV-1) Expressing a Mutant Form of ICP6 Stimulates a Strong Immune Response That Protects Mice against HSV-1-Induced Corneal Disease.
    J Virol. 2018;92.
    PubMed     Abstract available

  133. BROCK LG, Liu X, Liang B, Lingemann M, et al
    Murine Pneumonia Virus Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus from an Added Gene Is Highly Attenuated and Immunogenic in Rhesus Macaques.
    J Virol. 2018;92.
    PubMed     Abstract available

    August 2018
  134. WAN Z, Cardenas Garcia S, Liu J, Santos J, et al
    An alternative strategy as a quadrivalent live attenuated influenza virus vaccine.
    J Virol. 2018 Aug 22. pii: JVI.01025-18. doi: 10.1128/JVI.01025.
    PubMed     Abstract available

  135. SHAN C, Xie X, Zou J, Zust R, et al
    Using a virion assembly-defective dengue virus as a vaccine approach.
    J Virol. 2018 Aug 15. pii: JVI.01002-18. doi: 10.1128/JVI.01002.
    PubMed     Abstract available

  136. BLOOM DC, Tran RK, Feller J, Voellmy R, et al
    Immunization by Replication-Competent Controlled Herpesvirus Vectors.
    J Virol. 2018;92.
    PubMed     Abstract available

  137. MARIN-LOPEZ A, Calvo-Pinilla E, Barriales D, Lorenzo G, et al
    CD8 T Cell Responses to an Immunodominant Epitope within the Nonstructural Protein NS1 Provide Wide Immunoprotection against Bluetongue Virus in IFNAR(-/-) Mice.
    J Virol. 2018;92.
    PubMed     Abstract available

  138. PHILLIPS B, Van Rompay KKA, Rodriguez-Nieves J, Lorin C, et al
    Adjuvant-dependent enhancement of HIV Env-specific antibody responses in infant rhesus macaques.
    J Virol. 2018 Aug 8. pii: JVI.01051-18. doi: 10.1128/JVI.01051.
    PubMed     Abstract available

  139. PERMAR SR, Schleiss MR, Plotkin SA
    Reply to Gantt et al., "Higher Expectations for a Vaccine To Prevent Congenital Cytomegalovirus Infection".
    J Virol. 2018;92.

  140. GANTT S, Marchant A, Boppana SB
    Higher Expectations for a Vaccine To Prevent Congenital Cytomegalovirus Infection.
    J Virol. 2018;92.

  141. KIENER R, Fleischmann M, Wiegand MA, Lemmermann NAW, et al
    Efficient Delivery of Human Cytomegalovirus T Cell Antigens by Attenuated Sendai Virus Vectors.
    J Virol. 2018;92.
    PubMed     Abstract available

  142. KIM YJ, Kim KH, Ko EJ, Kim MC, et al
    Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain Specific HA or Cross Protective M2e vaccination.
    J Virol. 2018 Aug 1. pii: JVI.00969-18. doi: 10.1128/JVI.00969.
    PubMed     Abstract available

    July 2018
  143. STUART CA, Zhivkoplias EK, Senkevich TG, Wyatt LS, et al
    RNA polymerase mutations selected during experimental evolution enhance replication of a hybrid vaccinia virus with an intermediate transcription factor subunit replaced by the myxoma virus ortholog.
    J Virol. 2018 Jul 25. pii: JVI.01089-18. doi: 10.1128/JVI.01089.
    PubMed     Abstract available

  144. CHIUPPESI F, Nguyen J, Park S, Contreras H, et al
    Multi-Antigenic Modified Vaccinia Ankara Vaccine Vectors to Elicit Potent Humoral and Cellular Immune Reponses Against Human Cytomegalovirus in Mice.
    J Virol. 2018 Jul 25. pii: JVI.01012-18. doi: 10.1128/JVI.01012.
    PubMed     Abstract available

  145. BROECKER F, Liu STH, Sun W, Krammer F, et al
    Immunodominance of Antigenic Site B in the Hemagglutinin of the Current H3N2 Influenza Virus in Humans and Mice.
    J Virol. 2018 Jul 25. pii: JVI.01100-18. doi: 10.1128/JVI.01100.
    PubMed     Abstract available

  146. MILLER-NOVAK LK, Das J, Musich TA, Demberg T, et al
    Analysis of complement-mediated lysis of SIV and SIV-infected cells reveals sex differences in vaccine-induced immune responses in Rhesus macaques.
    J Virol. 2018 Jul 18. pii: JVI.00721-18. doi: 10.1128/JVI.00721.
    PubMed     Abstract available

  147. CHAN KW, Pan R, Costa M, Gorny MK, et al
    Structural Comparison of Human Anti-HIV-1 gp120 V3 MAbs of the Same Gene Usage Induced by Vaccination and Chronic Infection.
    J Virol. 2018 Jul 11. pii: JVI.00641-18. doi: 10.1128/JVI.00641.
    PubMed     Abstract available

  148. MEHTA N, Enwere EK, Dos Santos T, Saffran HA, et al
    Expression of the vaccinia virus anti-apoptotic F1 protein is blocked by PKR in the absence of the viral E3 protein.
    J Virol. 2018 Jul 11. pii: JVI.01167-18. doi: 10.1128/JVI.01167.
    PubMed     Abstract available

  149. HOVANESSIAN AG, Soundaramourty C, Benferhat R, Le Grand R, et al
    Vaccination with the conserved caveolin-1 binding motif in HIV-1 glycoprotein gp41 delays the onset of viral infection and provides partial protection in SHIV-challenged cynomolgus macaques.
    J Virol. 2018 Jul 5. pii: JVI.00370-18. doi: 10.1128/JVI.00370.
    PubMed     Abstract available

  150. MENACHERY VD, Gralinski LE, Mitchell HD, Dinnon KH 3rd, et al
    Combination attenuation offers strategy for live-attenuated coronavirus vaccines.
    J Virol. 2018 Jul 5. pii: JVI.00710-18. doi: 10.1128/JVI.00710.
    PubMed     Abstract available

  151. CAO QM, Ni YY, Cao D, Tian D, et al
    Recombinant Porcine Reproductive and Respiratory Syndrome Virus Expressing Membrane-Bound Interleukin-15 as an Immunomodulatory Adjuvant Enhances NK and gammadelta T Cell Responses and Confers Heterologous Protection.
    J Virol. 2018;92.
    PubMed     Abstract available

    June 2018
  152. ZHANG M, Sun Y, Chen W, Bu Z, et al
    The 135 gene of goatpox virus encodes an inhibitor of nuclear factor-kappaB and apoptosis and may serve as an improved insertion site to generate vectored live vaccine.
    J Virol. 2018 Jun 27. pii: JVI.00190-18. doi: 10.1128/JVI.00190.
    PubMed     Abstract available

  153. VIKTOROVA EG, Khattar SK, Kouiavskaia D, Laassri M, et al
    Newcastle Disease Virus-Based Vectored Vaccine against Poliomyelitis.
    J Virol. 2018 Jun 20. pii: JVI.00976-18. doi: 10.1128/JVI.00976.
    PubMed     Abstract available

  154. LI P, Ke X, Wang T, Tan Z, et al
    Zika Virus Attenuation by Codon Pair Deoptimization Induces Sterilizing Immunity in Mouse Models.
    J Virol. 2018 Jun 20. pii: JVI.00701-18. doi: 10.1128/JVI.00701.
    PubMed     Abstract available

  155. WALZ L, Kays SK, Zimmer G, von Messling V, et al
    Sialidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase Subtype.
    J Virol. 2018 Jun 20. pii: JVI.01006-18. doi: 10.1128/JVI.01006.
    PubMed     Abstract available

  156. KHAN AA, Srivastava R, Vahed H, Roy S, et al
    Human Asymptomatic Epitope Peptide/CXCL10-Based Prime/Pull Vaccine Induces Herpes Simplex Virus-Specific Gamma Interferon-Positive CD107(+) CD8(+) T Cells That Infiltrate the Cornea and Trigeminal Ganglia of Humanized HLA Transgenic Rabbits and Protec
    J Virol. 2018 Jun 13. pii: JVI.00535-18. doi: 10.1128/JVI.00535.
    PubMed     Abstract available

  157. MARTINS MA, Tully DC, Pedreno-Lopez N, von Bredow B, et al
    Mamu-B*17+ rhesus macaques vaccinated with env, vif, and nef manifest early control of SIVmac239 replication.
    J Virol. 2018 Jun 6. pii: JVI.00690-18. doi: 10.1128/JVI.00690.
    PubMed     Abstract available

  158. IAMPIETRO MJ, Larocca RA, Provine NM, Abbink P, et al
    Immunogenicity and Cross-Reactivity of Rhesus Adenoviral Vectors.
    J Virol. 2018;92.
    PubMed     Abstract available

    May 2018
  159. SINGH S, Ramirez-Salazar EG, Doueiri R, Valentin A, et al
    Control of Heterologous SIVsmE660 infection by DNA and Protein Co-immunization Regimens Combined with Different Toll-like Receptor-4 (TLR-4) Based Adjuvants in Macaques.
    J Virol. 2018 May 23. pii: JVI.00281-18. doi: 10.1128/JVI.00281.
    PubMed     Abstract available

  160. SULLIVAN NL, Reuter-Monslow MA, Sei J, Durr E, et al
    Breadth and functionality of varicella zoster virus glycoprotein-specific antibodies identified after Zostavax vaccination in humans.
    J Virol. 2018 May 9. pii: JVI.00269-18. doi: 10.1128/JVI.00269.
    PubMed     Abstract available

  161. ELSAYED H, Nabi G, McKinstry WJ, Khoo KK, et al
    Intrastructural Help: Harnessing T-Helper Cells Induced by Licensed Vaccines for Improvement of HIV Env Antibody Responses to Virus-Like Particle Vaccines.
    J Virol. 2018 May 9. pii: JVI.00141-18. doi: 10.1128/JVI.00141.
    PubMed     Abstract available

    April 2018
  162. SANTOS ROCHA C, Hirao LA, Weber MG, Mendez-Lagares G, et al
    Subclinical cytomegalovirus infection associates with altered host immunity, gut microbiota and vaccine responses.
    J Virol. 2018 Apr 18. pii: JVI.00167-18. doi: 10.1128/JVI.00167.
    PubMed     Abstract available

  163. OZOROWSKI G, Cupo A, Golabek M, LoPiccolo M, et al
    Effects of adjuvants on HIV-1 envelope glycoprotein SOSIP trimers in vitro.
    J Virol. 2018 Apr 18. pii: JVI.00381-18. doi: 10.1128/JVI.00381.
    PubMed     Abstract available

  164. BRICAULT CA, Kovacs JM, Badamchi-Zadeh A, McKee K, et al
    Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea Pigs.
    J Virol. 2018 Apr 11. pii: JVI.00369-18. doi: 10.1128/JVI.00369.
    PubMed     Abstract available

    March 2018
  165. CARNEC X, Mateo M, Page A, Reynard S, et al
    A vaccine platform against arenaviruses based on a recombinant hyper-attenuated Mopeia virus expressing heterologous glycoproteins.
    J Virol. 2018 Mar 28. pii: JVI.02230-17. doi: 10.1128/JVI.02230.
    PubMed     Abstract available

  166. BARBAN V, Mantel N, De Montfort A, Pagnon A, et al
    Improvement of Dengue Non-Human Primate Model via a Reverse Translational Approach Based on Dengue Vaccine Clinical Efficacy Data against Dengue 2 and Dengue 4.
    J Virol. 2018 Mar 28. pii: JVI.00440-18. doi: 10.1128/JVI.00440.
    PubMed     Abstract available

  167. WANG W, Song HS, Keller PW, Alvarado-Facundo E, et al
    Conformational stability of the hemagglutinin of H5N1 influenza A viruses influences susceptibility to broadly neutralizing stem antibodies.
    J Virol. 2018 Mar 28. pii: JVI.00247-18. doi: 10.1128/JVI.00247.
    PubMed     Abstract available

  168. ALJURAYYAN A, Puksuriwong S, Ahmed M, Sharma R, et al
    Activation and induction of antigen-specific T follicular helper cells (TFH) play a critical role in LAIV-induced human mucosal anti-influenza antibody response.
    J Virol. 2018 Mar 21. pii: JVI.00114-18. doi: 10.1128/JVI.00114.
    PubMed     Abstract available

  169. AGNIHOTHRAM S, Menachery VD, Yount BL Jr., Lindesmith LC, et al
    Development of a Broadly Accessible VEE Replicon Particle Vaccine Platform.
    J Virol. 2018 Mar 14. pii: JVI.00027-18. doi: 10.1128/JVI.00027.
    PubMed     Abstract available

  170. BRYK P, Brewer MG, Ward BM
    Vaccinia virus phospholipase protein F13 promotes the rapid entry of extracellular virions into cells.
    J Virol. 2018 Mar 14. pii: JVI.02154-17. doi: 10.1128/JVI.02154.
    PubMed     Abstract available

  171. LAW JLM, Logan M, Wong J, Kundu J, et al
    Role of the E2 hypervariable region (HVR1) in the immunogenicity of a recombinant HCV vaccine.
    J Virol. 2018 Mar 14. pii: JVI.02141-17. doi: 10.1128/JVI.02141.
    PubMed     Abstract available

  172. BLASS E, Aid M, Martinot AJ, Larocca RA, et al
    Adenovirus vector vaccination impacts NK cell rheostat function following LCMV infection.
    J Virol. 2018 Mar 7. pii: JVI.02103-17. doi: 10.1128/JVI.02103.
    PubMed     Abstract available

  173. LAZARO-FRIAS A, Gomez-Medina S, Sanchez-Sampedro L, Ljungberg K, et al
    Distinct Immunogenicity and Efficacy of Poxvirus-based Vaccine Candidates against Ebola Virus expressing GP and VP40 Proteins.
    J Virol. 2018 Mar 7. pii: JVI.00363-18. doi: 10.1128/JVI.00363.
    PubMed     Abstract available

  174. WAN Y, Kang G, Sreenivasan C, Daharsh L, et al
    A DNA vaccine expressing consensus hemagglutinin-esterase fusion protein protected guinea pigs from infection by two lineages of influenza D virus.
    J Virol. 2018 Mar 7. pii: JVI.00110-18. doi: 10.1128/JVI.00110.
    PubMed     Abstract available

    February 2018
  175. GU J, Hardy J, Boo I, Vietheer P, et al
    Escape of Hepatitis C virus from epitope I neutralization increases sensitivity of other neutralization epitopes.
    J Virol. 2018 Feb 21. pii: JVI.02066-17. doi: 10.1128/JVI.02066.
    PubMed     Abstract available

  176. POUYANFARD S, Spagnoli G, Bulli L, Balz K, et al
    Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses.
    J Virol. 2018;92.
    PubMed     Abstract available

  177. LIU R, Moss B
    Vaccinia virus C9 ankyrin-repeat/F-box protein is a newly identified antagonist of the type I interferon-induced antiviral state.
    J Virol. 2018 Feb 14. pii: JVI.00053-18. doi: 10.1128/JVI.00053.
    PubMed     Abstract available

  178. JEGASKANDA S, Mason RD, Andrews SF, Wheatley AK, et al
    Intranasal live influenza vaccine priming elicits localized B cell responses in mediastinal lymph nodes.
    J Virol. 2018 Feb 14. pii: JVI.01970-17. doi: 10.1128/JVI.01970.
    PubMed     Abstract available

  179. LOPES PP, Todorov G, Pham TT, Nesburn AB, et al
    Laser Adjuvant-Assisted Peptide Vaccine Promotes Skin Mobilization of Dendritic Cells and Enhances Protective CD8(+) TEM and TRM Cell Responses Against Herpes Infection and Disease(double dagger).
    J Virol. 2018 Feb 7. pii: JVI.02156-17. doi: 10.1128/JVI.02156.
    PubMed     Abstract available

  180. SAUNDERS KO, Santra S, Parks R, Yates NL, et al
    Immunogenicity of NYVAC prime-protein boost HIV-1 envelope vaccination and SHIV challenge of nonhuman primates.
    J Virol. 2018 Feb 7. pii: JVI.02035-17. doi: 10.1128/JVI.02035.
    PubMed     Abstract available

  181. WIJESUNDARA DK, Gummow J, Li Y, Yu W, et al
    Induction of genotype-cross reactive, hepatitis C virus-specific cell mediated immunity in DNA-vaccinated mice.
    J Virol. 2018 Feb 7. pii: JVI.02133-17. doi: 10.1128/JVI.02133.
    PubMed     Abstract available

    January 2018
  182. JANKOVICH JK, Chapman D, Hansen DT, Robida MD, et al
    Immunisation of pigs by DNA prime and recombinant vaccinia virus boost to identify and rank African swine fever virus immunogenic and protective proteins.
    J Virol. 2018 Jan 31. pii: JVI.02219-17. doi: 10.1128/JVI.02219.
    PubMed     Abstract available

  183. YATES NL, deCamp AC, Korber BT, Liao HX, et al
    HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees.
    J Virol. 2018 Jan 31. pii: JVI.01843-17. doi: 10.1128/JVI.01843.
    PubMed     Abstract available

  184. TORRENTS DE LA PENA A, de Taeye SW, Sliepen K, LaBranche CC, et al
    Immunogenicity in rabbits of SOSIP trimers from clades A, B and C, given individually, sequentially or in combinations.
    J Virol. 2018 Jan 24. pii: JVI.01957-17. doi: 10.1128/JVI.01957.
    PubMed     Abstract available

  185. PERMAR SR, Schleiss MR, Plotkin SA
    Advancing our understanding of protective maternal immunity as a guide for development of vaccines to reduce congenital cytomegalovirus infections.
    J Virol. 2018 Jan 17. pii: JVI.00030-18. doi: 10.1128/JVI.00030.
    PubMed     Abstract available

  186. WILLS S, Hwang KK, Liu P, Dennison SM, et al
    HIV-1 specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galcer Blocking and Phagocytosis.
    J Virol. 2018 Jan 10. pii: JVI.01552-17. doi: 10.1128/JVI.01552.
    PubMed     Abstract available

  187. MOSTAFA HH, Thompson TW, Konen AJ, Haenchen SD, et al
    Herpes Simplex Virus 1 Mutant with Point Mutations in UL39 Is Impaired for Acute Viral Replication in Mice, Establishment of Latency, and Explant-Induced Reactivation.
    J Virol. 2018 Jan 10. pii: JVI.01654-17. doi: 10.1128/JVI.01654.
    PubMed     Abstract available

  188. ABBINK P, Kirilova M, Boyd M, Mercado N, et al
    Rapid Cloning of Novel Rhesus Adenoviral Vaccine Vectors.
    J Virol. 2018 Jan 3. pii: JVI.01924-17. doi: 10.1128/JVI.01924.
    PubMed     Abstract available

  189. XU K, Song Y, Dai L, Zhang Y, et al
    Recombinant Chimpanzee Adenovirus Vaccine AdC7-M/E Protects against Zika Virus Infection and Testis Damage.
    J Virol. 2018 Jan 3. pii: JVI.01722-17. doi: 10.1128/JVI.01722.
    PubMed     Abstract available

    December 2017
  190. ROSTAD CA, Stobart CC, Todd SO, Molina SA, et al
    J Virol. 2017 Dec 20. pii: JVI.01568-17. doi: 10.1128/JVI.01568.
    PubMed     Abstract available

  191. LIANG R, Sun Y, Liu Y, Wang J, et al
    Major histocompatibility complex class I (FLA-E*01801) molecular structure in domestic cats demonstrates species-specific characteristics in presenting viral antigen peptides.
    J Virol. 2017 Dec 20. pii: JVI.01631-17. doi: 10.1128/JVI.01631.
    PubMed     Abstract available

  192. LI C, Zhou H, Zhang H, Wang S, et al
    Bioinformatics Analysis of Differential Innate Immune Signaling in Macrophages by Wild-Type Vaccinia Mature Virus and a Mutant Virus with a Deletion of the A26 Protein.
    J Virol. 2017;91.

  193. KASANI SK, Cheng HY, Yeh KE, Chang SJ, et al
    Reply to "Bioinformatics Analysis of Differential Innate Immune Signaling in Macrophages by Wild-Type Vaccinia Mature Virus and a Mutant Virus with a Deletion of the A26 Protein".
    J Virol. 2017;91.

  194. REIS AL, Goatley LC, Jabbar T, Sanchez-Cordon PJ, et al
    Deletion of the African Swine Fever Virus Gene DP148R Does Not Reduce Virus Replication in Culture but Reduces Virus Virulence in Pigs and Induces High Levels of Protection against Challenge.
    J Virol. 2017;91.
    PubMed     Abstract available

  195. JONES AT, Chamcha V, Kesavardhana S, Shen X, et al
    A trimeric HIV-1 envelope gp120 immunogen induces potent and broad anti-V1V2 loop antibodies against HIV-1 in rabbits and rhesus macaques.
    J Virol. 2017 Dec 13. pii: JVI.01796-17. doi: 10.1128/JVI.01796.
    PubMed     Abstract available

  196. CHEN C, Liu L, Xiao Y, Cui S, et al
    Structural insight into a human neutralizing antibody against influenza virus H7N9.
    J Virol. 2017 Dec 6. pii: JVI.01850-17. doi: 10.1128/JVI.01850.
    PubMed     Abstract available

  197. ROYER DJ, Carr DJJ
    Reply to "Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth?"
    J Virol. 2017;91.

  198. GHIASI H
    Highly Efficacious Novel Vaccine, Humoral Immunity, and Ocular Herpes Simplex Virus 1: Reality or Myth?
    J Virol. 2017;91.

    November 2017
  199. ERASMUS JH, Seymour RL, Kaelber JT, Kim DY, et al
    Novel insect-specific Eilat virus-based chimeric vaccine candidates provide durable, mono- and multi-valent, single dose protection against lethal alphavirus challenge.
    J Virol. 2017 Nov 29. pii: JVI.01274-17. doi: 10.1128/JVI.01274.
    PubMed     Abstract available

  200. MATASSOV D, Mire CE, Latham T, Geisbert JB, et al
    Single Dose Trivalent Vesiculovax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.
    J Virol. 2017 Nov 15. pii: JVI.01190-17. doi: 10.1128/JVI.01190.
    PubMed     Abstract available

  201. JERE KC, Chaguza C, Bar-Zeev N, Lowe J, et al
    Emergence of double- and triple-gene reassortant G1P[8] rotaviruses possessing a DS-1-like backbone post rotavirus vaccine introduction in Malawi.
    J Virol. 2017 Nov 15. pii: JVI.01246-17. doi: 10.1128/JVI.01246.
    PubMed     Abstract available

  202. MALHERBE DC, Mendy J, Vang L, Barnette PT, et al
    Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C SHIV Mucosal Challenge.
    J Virol. 2017 Nov 1. pii: JVI.01092-17. doi: 10.1128/JVI.01092.
    PubMed     Abstract available

  203. GRESETH MD, Czarnecki MW, Bluma MS, Traktman P, et al
    Isolation and Characterization of vDeltaI3 Confirms that the Vaccinia Virus SSB Plays an Essential Role in Viral Replication.
    J Virol. 2017 Nov 1. pii: JVI.01719-17. doi: 10.1128/JVI.01719.
    PubMed     Abstract available

  204. VAN ERP EA, van Kasteren PB, Guichelaar T, Ahout IML, et al
    In Vitro Enhancement of Respiratory Syncytial Virus Infection by Maternal Antibodies Does Not Explain Disease Severity in Infants.
    J Virol. 2017;91.
    PubMed     Abstract available

  205. MONTEAGUDO PL, Lacasta A, Lopez E, Bosch L, et al
    BA71DeltaCD2: a New Recombinant Live Attenuated African Swine Fever Virus with Cross-Protective Capabilities.
    J Virol. 2017;91.
    PubMed     Abstract available

  206. WARING BM, Sjaastad LE, Fiege JK, Fay EJ, et al
    microRNA-based attenuation of influenza virus across susceptible hosts.
    J Virol. 2017 Nov 1. pii: JVI.01741-17. doi: 10.1128/JVI.01741.
    PubMed     Abstract available

    October 2017
  207. WANG X, Ku Z, Zhang X, Ye X, et al
    Structure, Immunogenicity and Protective Mechanism of an Engineered Enterovirus 71-Like Particle Vaccine Mimicking 80S Empty Capsid.
    J Virol. 2017 Oct 25. pii: JVI.01330-17. doi: 10.1128/JVI.01330.
    PubMed     Abstract available

  208. BOGDANOFF WA, Perez EI, Lopez T, Arias CF, et al
    Structural basis for the escape of human astrovirus from antibody neutralization: broad implications for rational vaccine design.
    J Virol. 2017 Oct 25. pii: JVI.01546-17. doi: 10.1128/JVI.01546.
    PubMed     Abstract available

  209. YORK J, Nunberg JH
    Epistastic interactions within the Junin virus envelope glycoprotein complex provide an evolutionary barrier to reversion in the live-attenuated Candid#1 vaccine.
    J Virol. 2017 Oct 25. pii: JVI.01682-17. doi: 10.1128/JVI.01682.
    PubMed     Abstract available

  210. SCHONE D, Hrycak CP, Windmann S, Lapuente D, et al
    Immunodominance of Adenovirus-Derived CD8+ T Cell Epitopes Interferes with the Induction of Transgene-Specific Immunity in Adenovirus-Based Immunization.
    J Virol. 2017;91.
    PubMed     Abstract available

  211. MURA M, Combredet C, Najburg V, Sanchez David RY, et al
    Nonencapsidated 5' Copy-Back Defective Interfering Genomes Produced by Recombinant Measles Viruses Are Recognized by RIG-I and LGP2 but Not MDA5.
    J Virol. 2017;91.
    PubMed     Abstract available

  212. MCGUIRE EP, Fong Y, Toote C, Cunningham CK, et al
    HIV exposed infants vaccinated with a MF59/rgp120 vaccine have higher magnitude anti-V1V2 IgG responses than adults immunized with the same vaccine.
    J Virol. 2017 Oct 11. pii: JVI.01070-17. doi: 10.1128/JVI.01070.
    PubMed     Abstract available

  213. SHEN X, Basu R, Sawant S, Beaumont D, et al
    HIV-1 gp120 Protein and MVAgp140 Boost Immunogens Increase immunogenicity of a DNA/MVA HIV-1 Vaccine.
    J Virol. 2017 Oct 11. pii: JVI.01077-17. doi: 10.1128/JVI.01077.
    PubMed     Abstract available

  214. WONG TM, Allen JD, Bebin-Blackwell AG, Carter DM, et al
    COBRA HA elicits hemagglutination-inhibition antibodies against a panel of H3N2 influenza virus co-circulating variants.
    J Virol. 2017 Oct 4. pii: JVI.01581-17. doi: 10.1128/JVI.01581.
    PubMed     Abstract available

  215. CARTER DM, Darby CA, Johnson SK, Carlock MA, et al
    Elicitation of protective antibodies against a broad panel of H1N1 viruses in ferrets pre-immune to historical H1N1 influenza viruses.
    J Virol. 2017 Oct 4. pii: JVI.01283-17. doi: 10.1128/JVI.01283.
    PubMed     Abstract available

  216. GOFF PH, Hayashi T, He W, Yao S, et al
    Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands Work Additively via MyD88 To Induce Protective Antiviral Immunity in Mice.
    J Virol. 2017;91.
    PubMed     Abstract available

    September 2017
  217. URAKAMI A, Ngwe Tun MM, Moi ML, Sakurai A, et al
    Envelope-modified tetravalent dengue virus-like particle vaccine: implication for flavivirus vaccine design.
    J Virol. 2017 Sep 27. pii: JVI.01181-17. doi: 10.1128/JVI.01181.
    PubMed     Abstract available

  218. BAGRI P, Anipindi VC, Nguyen PV, Vitali D, et al
    A novel role for IL-17 in enhancing type 1 helper T cell immunity in the female genital tract following mucosal HSV-2 vaccination.
    J Virol. 2017 Sep 27. pii: JVI.01234-17. doi: 10.1128/JVI.01234.
    PubMed     Abstract available

  219. MOONEY AJ, Gabbard JD, Li Z, Dlugolenski DA, et al
    Vaccination with Recombinant Parainfluenza Virus 5 Expressing Neuraminidase Protects against Homologous and Heterologous Influenza Virus Challenge.
    J Virol. 2017 Sep 20. pii: JVI.01579-17. doi: 10.1128/JVI.01579.
    PubMed     Abstract available

  220. ANDERSEN TK, Zhou F, Cox R, Bogen B, et al
    A DNA vaccine that targets hemagglutinin to antigen presenting cells protects mice against H7 influenza.
    J Virol. 2017 Sep 20. pii: JVI.01340-17. doi: 10.1128/JVI.01340.
    PubMed     Abstract available

  221. RYERSON MR, Richards MM, Kvansakul M, Hawkins CJ, et al
    Vaccinia virus encodes a novel inhibitor of apoptosis that associates with the apoptosome.
    J Virol. 2017 Sep 13. pii: JVI.01385-17. doi: 10.1128/JVI.01385.
    PubMed     Abstract available

  222. SAUERMANN U, Radaelli A, Stolte-Leeb N, Raue K, et al
    Vector order determines protection against pathogenic simian immunodeficiency virus infection in a triple component vaccine by balancing CD4+ and CD8+ T-cell responses.
    J Virol. 2017 Sep 13. pii: JVI.01120-17. doi: 10.1128/JVI.01120.
    PubMed     Abstract available

  223. SULLIVAN JT, Sulli C, Nilo A, Yasmeen A, et al
    High-throughput Protein Engineering Improves the Antigenicity and Stability of Soluble HIV-1 Envelope Glycoprotein SOSIP Trimers.
    J Virol. 2017 Sep 6. pii: JVI.00862-17. doi: 10.1128/JVI.00862.
    PubMed     Abstract available

    August 2017
  224. BROOKE CB
    Population diversity and collective interactions during influenza virus replication and evolution.
    J Virol. 2017 Aug 30. pii: JVI.01164-17. doi: 10.1128/JVI.01164.
    PubMed     Abstract available

  225. LIU X, Liang B, Ngwuta J, Liu X, et al
    Attenuated human parainfluenza virus type 1 (HPIV1) expressing the respiratory syncytial virus (RSV) fusion F glycoprotein from an added gene: effects of pre-fusion stabilization and packaging of RSV F.
    J Virol. 2017 Aug 23. pii: JVI.01101-17. doi: 10.1128/JVI.01101.
    PubMed     Abstract available

    July 2017
  226. PHAN SI, Zengel JR, Wei H, Li Z, et al
    Parainfluenza virus 5 (PIV5) expressing wild-type or pre-fusion respiratory syncytial virus (RSV) fusion protein protect mice and cotton rats from RSV challenge.
    J Virol. 2017 Jul 26. pii: JVI.00560-17. doi: 10.1128/JVI.00560.
    PubMed     Abstract available

    May 2017
  227. SHEN X, Bogers WM, Yates NL, Ferrari G, et al
    Crosslinking of a CD4 Mimetic Miniprotein with HIV-1 Env gp140 Alters Kinetics and Specificities of Antibody Responses against HIV-1 Env in Macaques.
    J Virol. 2017 May 10. pii: JVI.00401-17. doi: 10.1128/JVI.00401.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Vaccines is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.